JMP reiterates NeoPharm at strong buy

NeoPharm, Inc. was reiterated at a strong buy by JMP Securities analyst Charles C. Duncan. The company reported second-quarter financial results that were below expectations but not necessarily a main focus for investors, according to the analyst. NeoPharm management emphasized its focus on commercialization efforts for cintredekin besudotox (CBtox) and advancements in the NeoLipid drugs, LE-SN38 and LEP-ETU. Shares of the Waukegan, Ill.-based biopharmaceutical company were up 7 cents, or 1.48%, at $4.79, on volume of 88,783 shares versus the three-month running average of 329,375 shares. (Nasdaq: NEOL)

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.